2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Nifty, Sensex extend gains for 4th week amid strong ...
India's TV ecosystem grows into diverse, multi-platf...
India administers over 1 crore HPV vaccine doses in ...
Nasdaq posts worst week since Covid-19 pandemic over...
FIIs pump Rs 1,11,950 crore into Indian stock market...
Quote on Nifty50?s recent movements and outlook for ...
Life Insurance Sector Update : Distribution under th...
Technical Forecast : Nifty scales 25800 level; upwar...
India's GDP growth projected at 7 pc for FY27, 25 bp...
India Strategy : Nifty-500 review: A quarter to reme...
